Document Type

Article

Language

eng

Publication Date

8-2020

Publisher

Future Science

Source Publication

Immunotherapy

Source ISSN

1750-743x

Abstract

The major current focus on treating rheumatoid arthritis is to put an end to long-term treatments and instead, specifically block widespread immunosuppression by developing antigen-specific tolerance, while also permitting an intact immune response toward other antigens to occur. There have been promising preclinical findings regarding adoptive Treg cells immunotherapy with a critically responsible function in the prevention of autoimmunity, tissue repair and regeneration, which make them an attractive candidate to develop effective therapeutic approaches to achieve this interesting concept in many human immune-mediated diseases, such as rheumatoid arthritis. Ex vivo or invivo manipulation protocols are not only utilized to correct Treg cells defect, but also to benefit from their specific immunosuppressive properties by identifying specific antigens that are expressed in the inflamedjoint. The methods able to address these deficiencies can be considered as a target for immunity interventions to restore appropriate immune function.

Comments

Accepted version. Immunotherapy, Vol. 12, No. 12 (August 2020): 933-946. DOI. © 2020 Future Science. Used with permission.

Download
tayebi_14633acc.docx (5014 kB)
ADA Accessible Version

Included in

Dentistry Commons

Share

COinS